Document Detail


Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
MedLine Citation:
PMID:  17916314     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate functional and anatomic effects of intravitreal bevacizumab (Avastin; Roche Pharma, Vienna, Austria) in patients with neovascular age-related macular degeneration (AMD) with large submacular hemorrhages.
DESIGN: Retrospective, clinical study.
METHODS: Twenty-one eyes of 19 AMD patients with choroidal neovascularization and large submacular hemorrhage involving the fovea comprising more than 50% of the total lesion area were evaluated. All patients completed at least four months of follow-up; 12 patients fulfilled 12 months or more of follow-up. Patients were treated with up to six intravitreal bevacizumab injections (1 mg/0.04 ml) at a minimum of four-week intervals. Changes from baseline visual acuity (VA) scores, retinal measurements by optical coherence tomography (OCT), angiographic lesion characteristics, and hemorrhage size were analyzed. A safety assessment was performed at all visits.
RESULTS: Intravitreal bevacizumab injections were well tolerated in all patients. At month 4, VA was stable or improved (visual loss of 3 acuity lines or fewer) in 100% and improved by at least 3 lines in 9.5%. Comparable results were found at month 12. On average, the central foveal thickness decreased significantly by 55 microm four weeks after the first injection (P < .001) and by 52 microm at month 4 (P = .002). A significant anatomic improvement also was found for maximum retinal thickness, minimum retinal thickness, and foveal volume (P < .05) and was maintained during four months of follow-up. Mean size of hemorrhage was significantly reduced from 19.7 mm(2) at baseline to 2.5 mm(2) at the four-month follow-up (P < .001).
CONCLUSIONS: Intravitreal bevacizumab seems to be a promising therapeutic option in eyes with neovascular AMD and large submacular hemorrhages, with a stabilization in VA and anatomic improvement.
Authors:
Eva Stifter; Stephan Michels; Franz Prager; Michael Georgopoulos; Kaija Polak; Cornelia Hirn; Ursula Schmidt-Erfurth
Related Documents :
7487614 - Results of the endophthalmitis vitrectomy study. a randomized trial of immediate vitrec...
16402954 - Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequen...
15234134 - Foveal reattachment after macula-off retinal detachment occurs faster after vitrectomy ...
19165424 - Role of intravitreal bevacizumab in the management of eales' disease.
25039544 - Comparison of short-term infusion regimens of n-acetylcysteine plus intravenous fluids,...
23934354 - Comparison between the short-term results of onlay and sublay mesh placement in the man...
Publication Detail:
Type:  Journal Article     Date:  2007-10-04
Journal Detail:
Title:  American journal of ophthalmology     Volume:  144     ISSN:  0002-9394     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-26     Completed Date:  2008-01-29     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  886-892     Citation Subset:  AIM; IM    
Affiliation:
Department of Ophthalmology, Medical University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Choroidal Neovascularization / drug therapy*,  etiology
Female
Follow-Up Studies
Humans
Injections
Macular Degeneration / complications,  drug therapy*
Male
Retina / pathology
Retinal Hemorrhage / drug therapy*,  etiology
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology
Vitreous Body
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systematic review of studies on the socioeconomic status of men who batter their intimate partners
Next Document:  Retinal detachment after laser in situ keratomileusis in myopic eyes.